Chatbot for Opioid Addiction

Overseen By Delta-Marie Lewis, BA

Age: 18+

Sex: Any

Trial Phase: Phase 1 & 2

Sponsor: Dimagi Inc.

Must be taking: Opioid treatment

Disqualifiers: Cognitive impairments, Unstable medical condition

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: Unknown

Duration: 12 weeks

55 Participants Needed

Trial Summary

What is the purpose of this trial?

The goal of this clinical trial is to learn if/how an AI chatbot can support patients who in recovery for substance use, specifically those who are receiving medication for opioid use disorder. Can the chatbot help lower drug use? Can the chatbot help improve clinical appointment adherence? Can the chatbot help patients build self-efficacy in leading their own recovery journey? Will the chatbot help reduce workload burden for primary care teams? Can the chatbot serve as a safe, useful and engaging tool to support patients? Researchers will investigate the effects of using a chatbot to support follow-up care for patients in opioid use recovery. Participants will: * Receive access to a chatbot for 12 weeks that they can use to prepare for upcoming clinical appointments, find community resources, learn about urge-surfing and wellness techniques, and query for assistance with other recovery-related information and tasks * Complete surveys and provide user feedback

Research Team

Y. Xian Ho, PhD

Principal Investigator

Dimagi Inc.

Jonathan Jackson, MEng

Principal Investigator

Dimagi Inc.

Eligibility Criteria

This trial is for individuals in recovery from opioid addiction who are currently on medication-assisted treatment. Participants should be willing to use an AI chatbot for support over a 12-week period and provide feedback through surveys.

Inclusion Criteria

I can take part in a remote interview.

Own or have reliable access to Wi-Fi or a cellular network

I am currently receiving treatment for opioid use disorder at MGH.

Exclusion Criteria

Has any cognitive, visual, or auditory impairments that may prevent the participant from using the chatbot on a mobile device

Unstable medical condition that compromises the ability to safely participate

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive access to a chatbot for 12 weeks to support follow-up care and recovery needs

12 weeks

Virtual interaction with the chatbot

Follow-up

Participants are monitored for changes in substance use disorder severity, psychological health, self-efficacy, and user satisfaction

4 weeks

Treatment Details

Interventions

• Chatbot

Trial Overview The study tests whether an AI chatbot can help patients with opioid use disorder by reducing drug use, improving appointment adherence, empowering self-management of recovery, and easing the workload of primary care teams.

Participant Groups

Group I: Chatbot Experimental Treatment 1 Intervention

Participants will receive access to a chatbot for 12 weeks that can be used from a mobile device to support follow-up care and recovery needs.

Who Is Running the Clinical Trial?

Dimagi Inc.

Lead Sponsor

Trials

10

Recruited

9,300+

University of California, Los Angeles

Collaborator

Trials

1,594

Recruited

10,430,000+

National Institute on Drug Abuse (NIDA)

Collaborator

Trials

2,658

Recruited

3,409,000+

Massachusetts General Hospital

Collaborator

Trials

3,066

Recruited

13,430,000+